Forum Topic News
  • Conversation: Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis

    • November 16, 2018 10:42 AM GMT
    • Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatm...

      The letter from the FDA gives permission for Vyera to proceed with dosing human subjects in its Phase 1 SAD study of VYR-006. Vyera intends to begin a multiple ascending dose study pending satisfactory completion of the SAD study.
      Toxoplasmosis is caused by the parasite Toxoplasma gondii, and more than 40 million people in the United States may be infected by the parasite, which can persist in the body for a lifetime. A toxoplasma infection could cause serious health problems ranging from flu-like symptoms to causing damage to the brain, eyes and other organs, particularly in pregnant women or individuals who have compromised immune systems.
      Read more: https://prn.to/2PyT0gg

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč